(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2008 (16.10.2008)

PCT

(10) International Publication Number
WO 2008/122858 A9

(51) International Patent Classification:
C07D 401/06 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/IB2008/000792

(22) International Filing Date: 25 March 2008 (25.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/910,379	5 April 2007 (05.04.2007)	US
60/976,546	1 October 2007 (01.10.2007)	US
61/031,554	26 February 2008 (26.02.2008)	US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CAMPETA, Anthony, Michael** [US/US]; Pfizer Global Research & Development, Easter Point Road, Groton, CT 06340 (US). **CHEKAL, Brian, Patrick** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **MCLAUGHLING, Robert, William** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **SINGER, Robert, Alan** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: CRYSTALLINE FORMS OF 6- [2- (METHYLCARBAMOYL) PHENYLSULFANYL] -3-E- [2- (PYRIDIN-2-YL) ETHENYL] INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS




FIG. 6

(57) Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6- [2- (methylcarbamoyl) phenyl sulfanyl] -3-E- [2- (pyridin-2- yl) ethenyl] indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.

WO 2008/122858 A9

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
7 May 2009

Date of publication of the revised international search report:
18 June 2009

(15) Information about Correction:
see Notice of 18 June 2009